硫酸沙丁胺醇雾化治疗小儿喘息性疾病的临床观察 点击下载
论文标题: 硫酸沙丁胺醇雾化治疗小儿喘息性疾病的临床观察
英文标题:
中文摘要: 目的:观察硫酸沙丁胺醇雾化治疗小儿喘息性疾病的疗效和安全性。方法:156例喘息性疾病患儿随机分为对照组(78例)和观察组(78例)。对照组患儿给予吸氧、抗感染、止咳化痰、氨茶碱等常规治疗;观察组患儿在对照组治疗的基础上给予硫酸沙丁胺醇注射液0.03 ml/kg,溶于0.9%氯化钠注射液2 ml中,放置面罩式雾化器中雾化治疗,每次5~10 min,每日2次。两组疗程均为5 d。观察两组患儿的临床疗效、喘息缓解时间、肺部啰音消失时间、平均住院天数及不良反应发生情况。结果:观察组患儿总有效率显著高于对照组,喘息缓解时间、肺部啰音消失时间、平均住院时间均显著短于对照组,差异均有统计学意义(P<0.05)。两组患儿治疗期间均未见明显不良反应发生。结论:在常规治疗的基础上,硫酸沙丁胺醇雾化治疗小儿喘息性疾病疗效显著,且安全性相当。
英文摘要: OBJECTIVE: To observe the efficacy and safety of salbutamol sulfate by atomized inhalation in the treatment of pediatric asthmatic disease. METHODS: 156 children with asthmatic disease were randomly divided into control group (78 cases) and observation group (78 cases). Control group was given oxygen inhalation, anti-infection, relieving cough and reducing phlegm, aminophylline and other conventional treatment; observation group was additionally given 0.03 ml/kg salbutamol sulfate, adding into 2 ml 0.9% Sodium chloride injection, putting into mask atomizer for nebulization, 5-10 min every time, twice a day. They were treated for 5 d. Clinical efficacy, asthma remission time, pulmonary rales disappearing time, average hospitalization days and incidence of adverse reactions in 2 groups were observed. RESULTS: The total effective rate in observation group was significantly higher than control group, asthma remission time, pulmonary rales disappearing time and average hospitalization days were significantly shorter than control group, the differences were statistically significant (P<0.05). There were obvious adverse reactions in 2 groups during treatment. CONCLUSIONS: Based on conventional treatment, salbutamol sulfate by atomized inhalation has obvious efficacy in the treatment of pediatric asthmatic disease, with good safety.
期刊: 2016年第27卷第15期
作者: 林勇,彭静君,李文成,黄波
英文作者: LIN Yong,PENG Jingjun,LI Wencheng,HUANG Bo
关键字: 硫酸沙丁胺醇;雾化;小儿喘息性疾病;疗效;安全性
KEYWORDS: Salbutamol sulfate; Atomization; Pediatric asthmatic disease; Efficacy; Safety
总下载数: 81次
本日下载数: 2次
本月下载数: 81次
文件大小: 619.60Kb

* 注:未经本站明确许可,任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作!